KALARIS THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
KALARIS THERAPEUTICS, INC. (KLRS) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $40.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $20.00M.
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $20.00M.
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $5.00M, a 85.71% decline year-over-year.
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $20.00M, a 42.86% decline year-over-year.
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $15.00M, a 84.21% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $95.00M, a 42.01% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $163.81M, a 10.44% increase from fiscal 2022.
- KALARIS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $148.33M, a 43.52% decline from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $40.00M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $20.00M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $15.00M 10-K · filed 2026-03-17 | |||
| 2024-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $25.00M derived: sum of 2 quarters · filed 2025-03-07 | $55.00M derived: sum of 3 quarters · filed 2025-03-07 | $95.00M 10-K · filed 2025-03-07 |
| 2024-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $50.00M derived: sum of 2 quarters · filed 2024-11-12 | $90.00M 10-Q · filed 2024-11-12 | $125.00M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | $30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $70.00M 10-Q · filed 2024-08-09 | $105.00M derived: sum of 3 quarters · filed 2025-03-07 | $140.00M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | $40.00M 10-Q · filed 2024-05-13 | $75.00M derived: sum of 2 quarters · filed 2025-03-07 | $110.00M derived: sum of 3 quarters · filed 2025-03-07 | $150.33M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $35.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $70.00M derived: sum of 2 quarters · filed 2025-03-07 | $110.33M derived: sum of 3 quarters · filed 2025-03-07 | $163.81M 10-K · filed 2025-03-07 |
| 2023-09-30 | $35.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $75.33M derived: sum of 2 quarters · filed 2024-11-12 | $128.81M 10-Q · filed 2024-11-12 | $179.82M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $40.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $93.81M 10-Q · filed 2024-08-09 | $144.82M derived: sum of 3 quarters · filed 2024-08-09 | $204.82M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $53.48M 10-Q · filed 2024-05-13 | $104.48M derived: sum of 2 quarters · filed 2024-05-13 | $164.48M derived: sum of 3 quarters · filed 2024-05-13 | $195.81M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $51.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $111.00M derived: sum of 2 quarters · filed 2024-03-15 | $142.33M derived: sum of 3 quarters · filed 2024-03-15 | $148.33M 10-K · filed 2024-03-15 |
| 2022-09-30 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $91.33M derived: sum of 2 quarters · filed 2023-11-02 | $97.33M 10-Q · filed 2023-11-02 | $129.93M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $31.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $37.33M 10-Q · filed 2023-08-03 | $69.92M derived: sum of 3 quarters · filed 2023-08-03 | $124.92M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $6.00M 10-Q · filed 2023-05-04 | $38.60M derived: sum of 2 quarters · filed 2023-05-04 | $93.60M derived: sum of 3 quarters · filed 2023-05-04 | $173.60M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $32.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $87.60M derived: sum of 2 quarters · filed 2023-02-15 | $167.60M derived: sum of 3 quarters · filed 2023-02-15 | $262.60M 10-K · filed 2023-02-15 |
| 2021-09-30 | $55.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $135.00M derived: sum of 2 quarters · filed 2022-11-03 | $230.00M 10-Q · filed 2022-11-03 | $290.00M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $80.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $175.00M 10-Q · filed 2022-08-04 | $235.00M derived: sum of 3 quarters · filed 2022-08-04 | $241.00M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $95.00M 10-Q · filed 2022-05-05 | $155.00M derived: sum of 2 quarters · filed 2022-05-05 | $161.00M derived: sum of 3 quarters · filed 2022-05-05 | $191.00M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $66.00M derived: sum of 2 quarters · filed 2022-02-10 | $96.00M derived: sum of 3 quarters · filed 2022-02-10 | $131.00M 10-K · filed 2022-02-10 |
| 2020-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $36.00M derived: sum of 2 quarters · filed 2021-11-05 | $71.00M 10-Q · filed 2021-11-05 | $106.00M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $65.00M 10-Q · filed 2021-08-06 | $100.00M derived: sum of 3 quarters · filed 2021-08-06 | |
| 2020-03-31 | $35.00M 10-Q · filed 2021-05-06 | $70.00M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $35.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $55.00M 10-K · filed 2021-02-12 | ||
| 2019-09-30 | $20.00M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |